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lood Transfusion
fter Myocardial Infarction
riend, Foe, or Double-Edged Sword?*
ernando Alfonso, MD, PHD
adrid, Spain
ombined mechanical and pharmacological interventions
onstitute the cornerstone of therapy for patients with
T-segment elevation myocardial infarction. Over the last
ecade, remarkable advances in primary angioplasty proce-
ures and adjuvant antithrombotic and antiplatelet therapies
ave led to significant improvements in procedural success
nd a drastic reduction in thrombotic complication rates.
owever, these interventions are now being used increas-
ngly in complex patients, who frequently have severe
ssociated comorbidities, which leads to an increased risk of
See page 624
leeding (1,2). Currently, major bleeding is feared as the
ost important noncardiac complication in patients under-
oing coronary interventions. Different studies have identi-
ed anemia as a strong “independent” predictor of adverse
vents and mortality in these patients (1,2). In this scenario,
nce prevention has failed, transfusion remains the only
vailable therapy. However, recent systematic reviews of
tudies on red blood cell transfusion in patients with
schemic heart disease indicate that routine transfusion is of
ittle clinical benefit and, in fact, may carry the potential for
dverse serious consequences (3,4) (Table 1). Therefore, the
ppropriateness of transfusion has come under intense
crutiny and many practitioners have adopted a restrictive
pproach to the use of blood products, especially when
rompted by “arbitrary” transfusions triggers. However, in
atients with ischemic heart disease, the use of transfusion
till remains rather liberal (3,4). Is transfusion a necessary evil?
In this issue of JACC: Cardiovascular Interventions, Ni-
olsky et al. (5) examined the large database of the random-
zed CADILLAC (Controlled Abciximab and Device In-
estigation to Lower Late Angioplasty Complications) trial
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.r
From Interventional Cardiology, Cardiac Department, Cardiovascular Institute,
an Carlos University Hospital, Madrid, Spain.o assess the prognostic impact of blood transfusion after
rimary angioplasty. This is the first study assessing the
mplications of transfusions in this setting. These investi-
ators found that transfusion was independently associated
ith major adverse events and, more importantly, with
0-days and 1-year mortality. However, is transfusion
ndeed a double-edged sword?
revious Studies
he landmark TRICC (Transfusion Requirement in Crit-
cal Care) randomized trial (6) of critically ill patients found
o benefit with the use of a liberal transfusion strategy to
aintain hemoglobin levels of 10 mg/dl as compared with a
estrictive approach where transfusions were only indicated
o patients with a hemoglobin level 7 mg/dl. In an early
tudy, Wu et al. (7) analyzed the large Medicare adminis-
rative database (79,000 patients with acute myocardial
nfarction, with and without ST-segment elevation, aged
65 years and managed largely conservatively) and sug-
ested that anemia at admission increased early and late
ortality. Transfusion was associated with a lower 30-day
ortality in patients with a hematocrit 33% at admission,
hereas transfused patients with hematocrit 36% had a
igher mortality. Subsequent studies in patients with ST-
egment elevation acute myocardial infarction consistently
emonstrated an increased mortality after transfusion that
ersisted after adjustment for potential confounders (8–10).
ata From the CADILLAC Trial
n an early study (1), the CADILLAC investigators dem-
nstrated that baseline anemia (hematocrit at initial presen-
ation39% for men and36% for women) was frequently
ound (12.8%) in patients undergoing primary angioplasty
nd this finding was strongly associated with early and
-year mortality (3-fold risk increase). Furthermore, after
djusting for potential confounders (patients with anemia
ad an adverse risk profile) either anemia or baseline
ematocrit was identified as the strongest independent pre-
ictor of 1-year mortality on multivariate analysis. Of
nterest, when added to these models, neither nadir hemat-
crit value nor blood transfusions, correlated with mortality
1). Finally, when adjusted for medication use (patients with
nemia were less likely to receive aspirin, beta-blockers, and
tatins) anemia continued to be an independent predictor of
ortality. These findings are of special interest considering
hat the CADILLAC trial was a randomized study where
atients with high hemorrhagic risks were excluded. There-
ore, it is likely that baseline anemia, bleeding complications
uring hospitalization, and transfusion requirements will be
uch higher in unselected real-world patients undergoing
rimary angioplasty. Interestingly enough, in this initial
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634tudies were required to assess whether “early transfusion”
ould improve the prognosis in these patients (1). In a
ubsequent report (2), the CADILLAC investigators de-
ived a set of 7 variables that were proportionally weighted
nto a risk score for 1-year mortality. This score was
ubsequently validated against the dataset of the STENT-
AMI (Stent Primary Angioplasty in MI) trial. Again,
nemia emerged as an independent predictor of 1-year
ortality. Transfusion was not selected for inclusion in the
risk score” but it remained unclear whether this variable
as indeed analyzed or excluded due to its interaction with
nemia.
In the current analysis of the CADILLAC trial (5), blood
ransfusion was strongly associated with adverse clinical
utcomes. Of the 4% of patients that received transfusions,
oughly 1 in 4 died and 1 in 2 suffered adverse clinical events
death, myocardial infarction, target vessel revascularization,
r stroke) at 1 year. Transfused patients had more adverse
aseline characteristics, larger myocardial infarctions, and
oorer procedural results. However, after careful statistical
djustment “transfusion”—but not anemia—was identified
s an independent predictor of mortality. Considering the
imilar dataset, what reasons could explain the differences
ound in the variables identified as predictive of the main
utcome measures? Stretching statistical multivariate mod-
ling remains a possibility, but when comparing these
eports, some important factors arise. First, in the current
tudy, 82 patients (4%) were excluded to avoid coronary
rtery bypass graft–related bleedings. Second, anemia and
ransfusion were so closely related that the resulting inter-
ction interfered with identification of the real culprit.
hird, in the present analysis, additional adjustment by
transfusion propensity” was the key element to unravel the
ntoward consequences of transfusion. It is clear that this
ind of analysis provides a more robust and reliable adjust-
ent than conventional multivariate models. Nikolsky et al.
Table 1. Adverse Consequences of Red Blood Cell Transfusion
General
Acute complications (acute reactions, infection, lung injury, renal failure)
Long-term consequences (immunomodulating problems)
Hemodynamic
Volume overload (preload)
Increased blood viscosity (afterload)
Changes in stored red blood cells
Morphologic changes in red blood cells (impaired advance into microvascular
bed)
Loss of 2,3-diphosphoglycerate (shift oxyhemoglobin dissociation curve)
Reduced nitric oxide bioactivity (impaired vasodilation, enhanced platelet
aggregation)
Hemolysis (release of vasoactive and pro-inﬂammatory substances)
Transfusion further deteriorates microcirculatory damage in patients with acute myocardial
infarction.5) should be commended for this comprehensive study suggesting, for the first time, that transfusion has deleteri-
us effects in patients undergoing primary coronary angio-
lasty. Therefore, the current study complements the large
ody of evidence suggesting harmful consequences of liberal
lood transfusions in other clinical scenarios (3,4,6).
Some issues, however, deserve consideration (5). First,
he study provides a post hoc analysis of prospectively
ollected data within the context of a large randomized trial.
ransfusion was a “post-randomization event” and any
ttempt to draw associations between post-randomization
ariables and clinical outcome has the potential risk of bias.
ikewise, adjusted effects may still be influenced by the
otential effects of unmeasured residual confounders. Sec-
nd, admission hematocrit was used in the analyses, but
adir hematocrit before transfusion was not available.
hird, causes of anemia could not be established, yet they
ave major prognostic implications. Fourth, indications for
ransfusion and timing of this therapy during admission
ere not assessed. Fifth, the potential effect of discontinu-
tion of concomitant antithrombotic drugs on outcome
easures was not investigated because this information was
ot routinely collected. Last but not least, predictors of
ortality in transfused patients could not be analyzed due to
ample size constrains. However, this information might be
otentially crucial regarding clinical decision making on
ransfusions requirements.
linical Implications
n patients with acute myocardial infarction, bleeding pre-
ention is of paramount importance. In the past, both
leeding and transfusion were considered nuisances rather
han potentially life-threatening complications. Currently,
he shift toward strategies that diminish bleeding risk while
aintaining efficacy in reducing ischemic complications is
lear. The role of new anticoagulants, potentially safer yet
qually effective, should be further investigated in these
atients. Minimization of blood loss during primary angio-
lasty appears essential. In this context, the radial approach
merges as an attractive strategy. In a meta-analysis of
andomized trials the radial access reduced major bleeding
omplications by 73% as compared with femoral access (11).
eripheral arterial disease is strongly associated with base-
ine anemia (1); therefore, the radial access appears partic-
larly attractive in these patients (1). This route, initially
eserved for elective patients, is increasingly used in selected
atients undergoing primary angioplasty (12).
Once prevention has failed, how should we treat anemic
atients with acute myocardial infarction? Although trans-
usion currently remains the only available therapy, the
tudy of Nikolsky et al. (5) provides compelling reasons to
hink twice before applying this double-edged sword ther-
peutic strategy. First of all, optimal transfusion thresholds
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635eity was highlighted because transfusion rates were 2.5
imes higher in the U.S. than in non-U.S. centers. Further,
ore than one-half of the patients receiving transfusions did
ot have moderate to severe bleeding and had a nadir
ematocrit 30%. In these situations, transfusion appears
o have particularly adverse consequences. A holistic ap-
roach, with individualized management, should be pursued
nd appropriate transfusion triggers should be tailored
ccording to the underlying clinical condition (hemody-
amic instability, active bleeding, comorbidities, revascular-
zation completeness).
As the authors have acknowledged, transfusion may
imply be a predictor of a predictor of an outcome, the
roverbial friend of a friend. Nevertheless, accumulated
vidence strongly suggests that in patients with acute
yocardial infarction transfusion may indeed become a real
foe.” Therefore, until more information is available, a
onservative approach–with restrictive indications of blood
roducts–appears warranted. Widespread adoption of re-
trictive transfusion strategies might significantly improve
linical outcomes in these patients, thus shifting this therapy
nto a trusting “friend.”
eprint requests and correspondence: Dr. Fernando Alfonso,
nterventional Cardiology, Cardiac Department, Cardiovascular
nstitute, San Carlos University Hospital, Plaza de Cristo Rey,
adrid 28040, Spain. E-mail: falf@hotmail.com.
EFERENCES
1. Nikolsky E, Aymong ED, Halkin A, et al. Impact of anemia in patients
with acute myocardial infarction undergoing primary percutaneous
coronary intervention. Analysis from the Controlled Abciximab and
Device Investigation to Lower Late Angioplasty Complications (CA-
DILLAC) trial. J Am Coll Cardiol 2004;44:547–53. i2. Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after
primary percutaneous coronary intervention for acute myocardial in-
farction. The CADILLAC Risk Score. J Am Coll Cardiol 2005;45:
1397–405.
3. Gerber DR. Transfusions of packed red blood cells in patients with
ischemic heart disease. Crit Care Med 2008;36:1068–74.
4. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the
critically ill: a systematic review of the literature. Crit Care Med
2008;36:2667–74.
5. Nikolsky E, Mehran R, Sadeghi HM, et al. Prognostic impact of blood
transfusion after primary angioplasty for acute myocardial infarction:
analysis from the CADILLAC (Controlled Abciximab and Device
Investigation to Lower Late Angioplasty Complications) trial. J Am
Coll Cardiol Intv 2009;2:624–32.
6. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, random-
ized, controlled clinical trial of transfusion requirement in critical care.
Transfusion Requirements in Critical Care Investigators, Canadian
Critical Care Trials Group. N Engl J Med 1999;340:409–17.
7. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood
transfusion in elderly patients with acute myocardial infarction. N Engl
J Med 2001;345:1230–6.
8. Jani SM, Smith DE, Share D, et al. Blood transfusion and in-hospital
outcomes in anemic patients with myocardial infarction undergoing
percutaneous coronary intervention. Clin Cardiol 2007;30 Suppl
2:II49–56.
9. Aronson D, Dann EJ, Bonstein L, et al. Impact of red blood cell
transfusion on clinical outcomes in patients with acute myocardial
infarction. Am J Cardiol 2008;102:115–9.
0. Shishehbor MH, Madhwal S, Rajagopal V, et al. Impact of blood
transfusion on short- and long-term mortality in patients with ST-
segment elevation myocardial infarction. J Am Coll Cardiol Intv
2009;2:46–53.
1. Jolly SS, Amlani S, Hamon M, Yusuf S, Mehta SR. Radial versus
femoral access for coronary angiography or intervention and the impact
on major bleeding and ischemic events: a systematic review and
meta-analysis of randomized trials. Am Heart J 2009;157:132–40.
2. Brasselet C, Tassan S, Nazeyrollas P, Hamon M, Metz D. Random-
ised comparison of femoral versus radial approach for percutaneous
coronary intervention using abciximab in acute myocardial infarction:
results of the FARMI trial. Heart 2007;93:1556–61.
ey Words: anemia  bleeding  transfusion  coronary
nterventions  acute myocardial infarction.
